Introduction
The natural course of epilepsy has been studied in various patient groups but seldom among adolescents and young adults. Most studies on epilepsy in young people have concentrated on childhood epilepsy and not adolescents on the verge of adulthood. Some forms of epilepsy are more likely to start during teenage years, including the idiopathic syndromes such as juvenile myoclonic epilepsy. Partial syndromes such as mesial temporal sclerosis can also have its debut in the teens. Common triggers during this period, when there are so many new things to experience, are sleep deprivation, photosensitivity, alcohol use, and major stress such as school-examinations. It has been shown that among patients with childhood-onset epilepsy one-third will have a poor long-term outcome in terms of persistent seizures after remission or no remission at all [1] . Studies on the general epilepsy population have shown that treatment is not always optimal and that it is possible to improve the care of these patients.
In 1999, Raty et al. studied a group of young people with uncomplicated epilepsy. Since then these adolescents have grown into young adults. The study in 1999 showed that 42% continued to have seizures despite of anti-epileptic drug (AED) treatment. A British group also confirmed that seizures remain uncontrolled in up to half of all people with epilepsy in the UK [2] .
Raty et al. concluded in 1999 that the treatment of young people with epilepsy could be improved. Traditional AEDs strongly dominated the market and the authors presumed that newly released drugs were underused in this group. They also reported a high rate of side-effects among patients using AEDs [3] [4] [5] [6] .
In 2001, Lhatoo et al. [7] found, in the general population with epilepsy, few changes in medication in the face of continued seizures, a lack of specificity in the choice of drugs and a reluctance to use newer anti-epileptic drugs in patients with resistant epilepsy.
There have been considerable changes in the use of AEDs over the last decade as many new drugs have been developed and successively more widely used. These new drugs have advantages over to the old ones in terms of their favourable pharmacokinetics, improved tolerability and lower potential for drug-interactions [8] . They widen our treatment spectrum and make it possible to optimise individual therapy [9] . Despite this, evidence of their superiority over older drugs is sparse [10] . Many researchers, among them Brodie and French [11] , have pointed out that a wider use of new AEDs could improve the situation for many epilepsy patients.
Traditional AEDs remain first choice for most patients, but for special situations and populations a new AED may be recommended as reasonable first-line therapy [12] . This includes lamotrigine (LTG) as an alternative to valproate (VPA) in idiopathic generalized seizures in fertile women. A Spanish study in 2005 showed that women are more likely to be treated with a new AED and seem to have less adverse reactions [13] . Their results indicate that it is more difficult to control seizures in women. The underlying aetiology is an important factor as to whether patients develop intractable seizures or not [14] but there is no proof that there is a gender difference regarding refractory epilepsy.
This study compared seizure frequency and AED treatment 2004 with the situation 5 years earlier amongst young people with uncomplicated epilepsy. We also looked for differences between the genders concerning use of AEDs, seizure-frequency, sideeffects and reported quality-of-life (QOL). We also analysed the material for prognostic factors.
Materials and methods

Subjects
In 1999, Raty et al. studied adolescents at four Swedish hospitals. Adolescents aged 13-22 with uncomplicated epilepsy were invited to participate in that study and 82% accepted (n = 151). Raty et al. studied the medical and psychosocial characteristics of these young people with epilepsy. In 2004 a 5-year follow-up study was done. These young adults, now aged 18-27 years, were asked to complete the same questionnaires as in 1999. At the time of follow-up, 146 subjects were traceable and 97 returned the questionnaires. More women than men completed the questionnaires.
Analyses revealed no differences between the participants and the drop-outs with respect to socio-demographic factors, selfesteem, sense of coherence, problem areas, competence, or in terms of measured medical epilepsy-related factors.
Definitions
The diagnosis of epilepsy in 1999 was defined as having had at least two unprovoked epileptic seizures. Uncomplicated epilepsy was defined as epilepsy with no initially associated neurological impairment (mental retardation or cerebral palsy).
Inclusion/exclusion criteria
To be included in the group when it formed in 1999, adolescents had to have experienced at least one epileptic seizure during the previous year and/or to be on anti-epileptic drug treatment for epilepsy. Exclusion criteria were diseases or handicaps that were considered to have a substantial impact on quality-of-life. Patients with epilepsy classified as benign childhood epilepsy were also excluded in the original study 1999.
Instruments
A modified version of the National Hospital Seizure Severity Scale, NHS3 (Donoghue 1994, Swedish translation Malmgren 1994) was used both in 1999 and 2004. The question about seizure type was replaced by one where patients were asked to describe their seizures. Three questions were added concerning seizure frequency, drug treatment and side-effects of AED. To measure quality-of-life in 2004 we used the generic version of Quality-ofLife Index (QLI), written in Swedish. The instrument consists of two parts, each containing 34 items. It measures a person's satisfaction with various aspects of life and how important these aspects are to the person. It covers health and function, socio-economic status, psychological/spiritual and family. The scale is six-graded and ranges from 1 = very dissatisfied/very unimportant to 6 = very satisfied/very important. The maximum score is 30. QLI has previously been described in detail in an article published 2007 [15] . The QLI was classified as low if they scored less than 20, intermediate if they scored between 20 and 25 and high if the total score exceeded 25.
Procedure
Patients participating in 1999 were identified and invited by mail to participate in the follow-up study. Those who accepted gave their written consent. The invitation included information about the study, four questionnaires on quality-of-life, medical and psychosocial aspects of epilepsy, a written consent formula regarding permission to obtain information from the patient's medical record and a prepaid envelope in which to mail the response.
Patients who did not return their questionnaires within two weeks were contacted by phone or by mail if phone-calls were not answered. Data was also collected from the patient's medical records by two of the authors (H.G. and B.S.).
Classification of epileptic seizures was made according to the classification of the International League Against Epilepsy (ILAE) [16] .
To classify how well the seizures were controlled we used the same classification as Eriksson [17] . This classification was used in 1999 and also in 2004 to enable comparison. 
Analyses
For statistical analyses the Statistical Package for Social Sciences version 12.0 was used. Frequencies were calculated and cross-tabulations were carried out. Descriptives were presented as numbers and percentages in variables at nominal level. Non-parametric analyses used were Mann-Whitney's U-test, Kruskal-Wallis test and Fisher's exact test for comparison between independent groups. Wilcoxon sign-ranks test was used for comparison between dependent groups. p-Values less than 0.05 were considered significant.
Ethics
The regional research committees of Linkö ping and Ö rebro, Sweden approved this study. Those who participated gave their verbal and/or written consent. Written and verbal information were given to all medical staff concerned.
Results
In 2004, 97 participants, 37 men and 60 women completed the questionnaires. They were between 18 and 27 years old and had suffered from epilepsy at least 5 years. Some of the participants (n = 21) considered themselves recovered from epilepsy. They were all seizure-free, did not use any AEDs and reported no or only scarce contact with their neurologist. There were more women than men in this group (p < 0.05). There was no correlation between the classification set in 1999 and recovery. No significant differences regarding other demographic factors were shown. Most of these participants were also seizure-free in 1999, but were still using AEDs at that time.
The other participants (n = 76) still suffered from epilepsy and all but one used AED.
Among those still suffering from epilepsy 41% were classified as localisation-related epilepsy and 59% generalized epilepsy according to Table 1 .
More than half (57.9%) of these participants were seizure-free. The group with pharmaco-resistent seizures had increased slightly from 11.8% (n = 10) to 15.8% (n = 12).
Three persons had gone through ablation of the epilepsy focus and three persons had a vagus nerve stimulator implanted. Despite these procedures only one of these six participants had benefited substantially.
There was no significant change in seizure frequency for the whole group in 2004 compared to 1999. Participants that had recovered were seizure-free even in 1999, but most of them used medication then. There were no gender differences regarding seizure frequency in 1999, but more men than women had good control of seizures in 2004 (p < 0.05). Among the participants that still used AED, 77% of the men had good control of seizures, compared with 45% of the women. Of these men 75% used monotherapy with old generation AED compared with 45% of the women.
The use of new AEDs had increased since 1999 (p < 0.05). More women participants had received first-line treatment with a new generation AED than men (p < 0.05). More men than women were still prescribed monotherapy with a traditional AED in 2004 (p < 0.05). While men used valproicacid and carbamazepine to the same extent as in 1999 there was a shift from these substances to the use of new AEDs in women. The old AED withdrawn was usually substituted by lamotrigine in monotherapy or in combination with other drugs. Of AED users in this study 54% of women and 33% of men used lamotrigine at follow-up (Table 2) .
Among the participants who had good control of seizures 61% were treated with monotherapy of a traditional AED while 25% used monotherapy with a new AED. In the group with poor control of epilepsy nobody used monotherapy with traditional AED, while 67% used poly-therapy and 33% new AED.
There were no significant differences in the number of sideeffects reported between 1999 and 2004, and there had been no serious reactions such as anaphylaxis or liver toxicity. Tiredness still dominated but apart from that the picture was diverse including concentration difficulties, nausea, sleeping difficulties tremor and weight-gain or loss. No gender differences could be found and no correlation with the type of AED used. We found no significant differences in cognitive side-effects between various substances used.
The reported mean QLI score for overall QOL was 21.87 (S.D. 3.78), with approximately equal scores for men and women (21.44 compared to 22.00). The QLI score ranged from 11.70 to 29.43. Participants who had recovered from epilepsy had a better QOL than those still suffering from the disease (p < 0.05). The group who received the lowest scores for QOL had the highest seizurefrequency (p < 0.05). There were no significant gender differences regarding QOL. Participants with di-or poly-therapy scored lower than participants with monotherapy (p < 0.05). There was no correlation between QOL and the presence of AED side-effects in general. The group who described cognitive side-effects had a lower QOL than those who did not (p < 0.05).
Discussion
There have been considerable changes in the use of antiepileptic drugs over the last decade. Although traditional AEDs, such as carbamazepine (CBZ) and valproate (VPA) remain first drug of choice, new AEDs have increased the ability to customise treatment for each patient. We studied the situation for a group of adolescents with uncomplicated epilepsy and compared their present situation with their situation 5 years earlier. The drop-out was quite high, especially among men. More women than men had recovered from epilepsy, indicating a higher drop-out among men who no longer suffered from seizures. One reason for this could be that youngsters who have recovered from epilepsy do not want to be reminded of the disease and their interest in participating in a study was probably lower than before. In the group studied 21 out of 97 participants had recovered. Sillanpä ä and Schmidt [1] studied childhood epilepsy and found that a higher proportion recovered than we found in this study. The actual chance of recovering from epilepsy in adolescence is probably higher than our results indicate because of the drop-outs in our study. As expected adolescents were prescribed new AEDs to a greater extent in 2004 than 5 years earlier. This study shows that there are differences between the genders; more young women than young men are now being treated with new-generation AEDs, but their effectiveness in controlling seizures is lower in women. Apart from teratogenicity, menstrual cycle disorders and reduced fertility have been associated with AEDs [18] , making the choice of AED for women patients more complex. New AEDs appear to be more favourable than the older ones for treating fertile women [12] . This was the subject of intense discussion in the early 2000s resulting in many neurologists changing AED treatment primarily in womenpatients. LTG is an alternative to VPA as first drug of choice in generalized idiopathic seizures in women of childbearing potential [12] . The increase in use of LTG among women in this study can be due to the introduction of new guidelines and correspond so the diminished use of VPA. LTG may be less teratogenic in humans than other AEDs, although orofacial clefts have been reported [19] . The effects of polytherapy appear to carry greater risks and VPA appears to be associated with the highest risk of all during pregnancy, becoming more evident as doses exceed 1000 mg/day [19] . Data from pregnancy registers not only confirm that VPA is teratogenic but also that it may be associated with neurodevelopmental delay and autistic spectrum disorders in children exposed to the drug during pregnancy [20] . The physician must weigh benefits of seizure freedom for their female patients against the potential long-term consequences for the infants of these patients [21] .
Differences in cognitive side-effects between LTG and VPA have been found by other researchers in favour of LTG [22] , but could not be confirmed in this study. The participants in this study were asked to describe side-effects, not to grade them, so we cannot draw conclusions about the severity of the cognitive side-effects for each substance. LTG has also the potential to improve qualityof-life compared to VPA [23] . The SANAD study indicated that LTG was clinically better than CBZ for time to treatment failure for partial seizures [24] . In this study seizure frequency was higher for women than for men and these women used new AEDs, usually LTG, a fact that does not support the notion that new generation AEDs are more effective than the old ones.
The participants in this study reported no reduction in QOL compared with the US general population. This corresponds to findings in other studies of QOL of epilepsy in remission [25] . Among studies focusing on patients with intractable epilepsy the picture is different, with a substantial impact on QOL. The group in this study had uncomplicated epilepsy and most participants were fairly well controlled regarding seizure frequency. The fact that only a few participants suffered from intractable seizures can explain the high QOL in the present study. Frequency of seizures is the most important factor influencing QOL in this study of adolescents. This has previously been shown in adults [26] . Senol et al. [27] found that other important factors influence QOL in particular fatigue and depression. Participants with polytherapy have a lower QOL than the ones who use monotherapy. Adverse effects of AED are common and can have a considerable impact on QOL [28] . Cognitive side-effects in this study were the only adverse effects associated with a lower QOL. Benavente-Aguilar wrote in 2004 that medication neurotoxicity was associated with a lower quality-of-life, over and above the effect of the severity of the illness [29] . For young people who study or want to start working the cognitive impairments are of particular concern. Boylan et al. [30] have expressed concern that AED-related depression could reduce QOL if seizures are treated over-enthusiastically. There is also report of an improvement in QOL if AED can be withdrawn [31] . In agreement with other studies we saw an increasing incidence of side-effects with increasing numbers of agents used.
We studied these young people during the period in of their lives when major changes occur. That means that the life-situation of the participants was in no way constant during the time of the study. They moved, met new partners, began new studies and new jobs. We assumed that this age-group would be more interested in trying new drugs than older patients, but younger people are more difficult to trace and may also have a higher drop-out rate. The questionnaires used were time-consuming, which can have inhibited participation. The group was also heterogeneous, consisting of people with epilepsy of different classification being treated with different combinations of medications, which results in difficulty in drawing conclusions about any special group. Despite this the study provides information about the use of new AEDs in the clinical setting. AEDs are given to a miscellaneous group of patients, which is reflected in this study. When a new drug is released it is first used in combination with other drugs and only later as mono-therapy. The treatment of epilepsy patients is and should continue to be individualised. These factors however, make it more difficult to study this group in a natural manner.
One bias when using questionnaires might be that the patients who choose to participate could be more seriously ill and because of that more interested than those who declined. The fact that 21% of those answering the questionnaires considered themselves to be healthy also indicates that patients who had recovered from epilepsy had an interest in participating.
In this study we could not show that seizure frequency in this group of patients had improved since the introduction of new generation AEDs. It may be that this study is too small to demonstrate any difference. It can also reflect the severity of epilepsy; participants with more severe epilepsy can have been given new generation AED more generously, as the incentive to make changes of medication is greater. It may also depend on the fact that physicians have not yet learnt to use these drugs in an optimal way. On the other hand, the QOL was normal for the participants of this study meaning that the increase in number of choices of AED can actually have given physicians the opportunity to adjust treatment to suit the individual patient in a better way than before. Many factors influence the well-being of our patients making the choice of AED for each patient complex. More studies are needed to better understand how these factors interact.
Conclusions
This study indicates that more women than men are treated with new generation AEDs, and the increase in use of new AEDs does not lead to a reduction in seizure frequency in young adults. It further indicates that effectiveness in controlling seizures is lower in women in the age-group studied. Further studies are required to better understand how epilepsy-related factors interact.
